Category Archives: FDA Policy

Mid-Year Check on the Pace of New Drug Approvals at FDA

At the mid-year point, I usually do a check-in to see how we are doing on new drug approvals and how it compares to years gone by. I am quite tardy checking in on that front, so let’s get it … Continue reading

Posted in FDA Policy | Comments Off on Mid-Year Check on the Pace of New Drug Approvals at FDA

What They Said – FDA Press Releases 2d Quarter 2018

A personal note – Apologies – I have been lagging on postings following a bereavement.  As each quarter ends, it has been an Eye on FDA practice to look back and compare different types of activities to assess any changes … Continue reading

Posted in FDA Image, FDA Policy | 2 Comments

A (Slight) Liberalization of Communications with Docs from FDA

What Happened. This week FDA issued a new final guidance related to communications about medical products that, while representing a slight liberalization of regulation when it comes to discussing useful information about a drug and the cleared uses for it, … Continue reading

Posted in FDA Policy | Comments Off on A (Slight) Liberalization of Communications with Docs from FDA

The Back and Forth on Safety Versus Speed and FDA

This week the Commissioner issued a statement related to the proposed modernization of the FDA’s drug review office, also the subject of a blog post by FDA’s head of the Center for Drug Evaluation and Research Janet Woodcock. While focused … Continue reading

Posted in FDA Policy | Comments Off on The Back and Forth on Safety Versus Speed and FDA

FDA and The Scarlet Letter

FDA apparently intends to implement today an idea that has been kicking around for a while to begin publishing the names of companies that have had letters of complaint lodged against them asserting that they are taking actions to block … Continue reading

Posted in FDA Policy, Generic Drugs | 1 Comment